FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream

AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Published
11 Feb 25
Updated
31 Jul 25
AnalystConsensusTarget's Fair Value
UK£26.59
6.2% undervalued intrinsic discount
31 Jul
UK£24.95
Loading
1Y
44.2%
7D
0.6%

Author's Valuation

UK£26.6

6.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on26 Mar 25
Fair value Increased 8.76%

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on13 Mar 25
Fair value Decreased 7.79%

AnalystConsensusTarget has increased revenue growth from 3.4% to 4.0%, increased profit margin from 8.0% to 9.5% and decreased future PE multiple from 33.4x to 27.5x.